Drug Profile
TT 14
Alternative Names: GPC3-CAR VST; GPC3-CAR VST - Tessa Therapeutics; TT14Latest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator Tessa Therapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for preclinical development in Solid-tumours in Singapore (Parenteral)
- 02 Jan 2018 Preclinical trials in Solid tumours in Singapore (Parenteral) before January 2018 (Tessa Therapeutics pipeline, January 2018)